95 results about "Antigen Targeting" patented technology

The invention discloses an antibody-coupled drug combination prediction method based on a virtual graph and multi-scale characteristics, provides a method for constructing initial characteristics of a drug carrier, a linker, an antibody heavy chain and light chain and an antigen target protein, provides a method for extracting drug sequence characteristics by using 1DCNN, and designs a drug characteristic extraction method based on graph virtual nodes. Virtual nodes and virtual edges are introduced into a molecular structure diagram, a Graph Transform is used as a diagram feature extractor, virtual node features are used as drug representation, then protein and drug features are input into a feature fusion module, an attention mechanism and a gating jump connection mechanism are added in feature fusion, and the protein and drug features are fused. And the feature information of different hidden layers is fused while the potential interaction is captured, so that higher-precision affinity prediction is realized. The method can solve the technical problem that the structural features of the antibody-coupled drug are difficult to extract in the prior art and the technical problem that the features of different components are difficult to fuse.

The invention relates to the field of biotechnology and cell therapy, in particular to a recombinant construct, a CAR (chimeric antigen receptor) modified cell and application. On the objective basis of different antigen target spots, such as CD19, CLDN18.2 or BCMA and other different antigen target spots corresponding to abnormal expression of tumors, the target spots are used as target spots for clinical treatment; under the condition that the expression of the chimeric antigen is not changed, two cell factors are secreted synergistically; the long-term treatment effect of immune cells is enhanced, and meanwhile, the treatment risk is reduced.

The present invention relates to a recombinant chimeric antigen targeting poxvirus (particularly monkeypox virus), a subunit vaccine thereof, and its application. The recombinant chimeric antigen of the present invention comprises two immunogens arranged in a specific manner: monkeypox virus A35 protein or its antigenic fragment (or its derivative peptide segment) and monkeypox virus M1 protein or its antigenic fragment (or its derivative peptide segment), which can stimulate immune responses against two infectious virus particles: intracellular mature virus particles (IMV) and extracellular enveloped virus particles (EEV), thereby efficiently stimulating specific immune protection against monkeypox virus. In addition, the poxvirus vaccine of the present invention also has good safety, rapid responsiveness and production capacity support, and has excellent clinical application prospects.

The present application relates to nanoparticles comprising (a) an amphiphilic polymer; (b) a first lipid comprising a polar head group and a non-polar tail group; and (c) a peptide comprising a T cell epitope. Also disclosed are populations of said nanoparticles, processes for manufacturing said nanoparticles, precursors for manufacturing said nanoparticles, pharmaceutical compositions of said nanoparticles, and methods of treating a disease or disorder comprising administering said nanoparticles to a subject.

The invention relates to the field of biotechnology and targeted therapy, in particular to a recombinant construct, a recombinant oncolytic virus and construction and application of the recombinant oncolytic virus. The virus takes a wild poxvirus genome as a skeleton, thymokinase TK genes are deleted through homologous recombination, and a poxvirus P-se / l promoter is used for promoting expression of a CD19 membrane localization antibody. The constructed recombinant oncopoxvirus aCD19-TM-OVV can improve the infection efficiency and gene delivery efficiency on B lymphoma in a CD19 antigen target-dependent manner, promote virus replication of the oncopoxvirus in CD19 positive B lymphoma cells, and significantly enhance the tumor growth inhibition effect on the CD19 positive B lymphoma cells in vitro and in mouse B lymphoma models.

The present invention provides neutralizing monoclonal antibodies targeting Nipah virus G protein and their uses, wherein the monoclonal antibodies can recognize Nipah virus G protein. The present invention uses NiV G protein as an antigen target, displays antigens on a ferritin nanoparticle platform to immunize mice, and screens out three monoclonal antibodies that can specifically bind to NiV G protein. Antibody epitope competition experiments found that the S1E2 and SB10 monoclonal antibodies among these three antibodies recognize new epitopes of NiV G protein that have not been reported before. In vitro neutralization experiments have demonstrated that these three antibodies have high in vitro neutralizing activity, and can neutralize both NiV-M and NiV-B strains, with the characteristics of high expression and good stability, and can be used to prepare virus detection products such as Nipah and Hendra or drugs for preventing and treating Nipah and Hendra virus diseases.

The application provides an autoantibody marker for predicting the effect of lung cancer immunneoadjuvant therapy on lung cancer patients in the third stage, a series of autoantibody marker molecules are screened by detecting autoantibodies against different antigen targets in blood of lung cancer patients in the third stage, and the autoantibody marker molecules have great correlation with the prediction of the effect of lung cancer immunneoadjuvant therapy, and three autoantibody biomarkers with better prediction of the effect of lung cancer immunneoadjuvant therapy on lung cancer patients in the third stage are further screened by combining with a CART decision tree strategy; the combination of the autoantibody biomarkers can be used for efficiently predicting whether the lung cancer immunneoadjuvant therapy on lung cancer patients in the third stage is effective, providing a reference basis for a clinician to decide a treatment scheme, providing a new prediction means for the effect of lung cancer immunneoadjuvant therapy on lung cancer patients in the third stage, and having important scientific significance and clinical application value.

The invention discloses a hepatocellular carcinoma prognosis and treatment adaptability evaluation model based on mRNA vaccine antigen and a construction method. The method comprises the following steps: firstly, analyzing gene expression difference between normal tissues and hepatocellular carcinoma tumors, understanding mutation and genome structure change of hepatocellular carcinoma patients, and then further selecting genes related to the infiltration level of antigen presenting cells from abnormally expressed genes and mutant genes, and the genes having a significant relationship with the overall lifetime and disease-free lifetime of the patient, so as to obtain candidate mRNA vaccine neoantigen targets. Based on the expression level of the target, immunotyping is performed on the patient, and the patient population suitable for the mRNA vaccine is evaluated. Meanwhile, the relationship between the expression level of the target spot and the prognosis of the patient is quantified, so that the probability value that the total survival time of the hepatocellular carcinoma patient reaches 3 years and 5 years is predicted. According to the invention, the hepatocellular carcinoma treatment resistance and tumor immune state can be objectively and accurately evaluated, and the prediction accuracy of hepatocellular carcinoma treatment prognosis is improved.

The invention provides a double-target chimeric antigen receptor, a CAR-T cell and application of the double-target chimeric antigen receptor and the CAR-T cell, and belongs to the technical field of hybrid peptides. The double-target chimeric antigen receptor comprises EGFRvIII scFv and GRP78 scFv; the nucleotide sequence of the EGFRvIII scFv is as shown in SEQ ID NO. 2; and the nucleotide sequence of the GRP78 scFv is as shown in SEQ ID NO. 4. According to the invention, by targeting two antigen targets of EGFRvIII and GRP78, the targeting specificity is enhanced, and the ability of CAR-T cells to kill glioblastoma is enhanced. Compared with a single-target CAR-T cell (EGFRvIII-CAR-T cell or GRP78-CAR-T cell), the T cell modified by the double-target chimeric antigen receptor provided by the invention has better cell factor secretion capability and better killing effect on tumor cells.

The present invention relates to an immunoglobulin derived single-chain fragment variable (scFv) that broadly binds HLA II molecules and uses thereof. In particular, targeting of an antigen to antigen presenting cells with the HLAII-specific targeting unit provided herein find use in enhancing immune responses after vaccination.

The application discloses an anti-RAGE antibody, which can target RAGE antigen targets of different species such as human, murine and monkey. The application further discloses a conjugate, a bispecific antibody, a multispecific antibody, an immune cell, and a fusion protein which respectively comprises the anti-RAGE antibody, and further discloses a method for displaying the anti-RAGE antibody on extracellular vesicles. The anti-RAGE antibody provided by the application is applied to display on extracellular vesicles, endowing the extracellular vesicles with targeting ability, and finally enriching the extracellular vesicles in specific lesion tissues or organs with high expression of RAGE antigens, thereby facilitating the delivery, release and therapeutic effects of other drug molecules loaded on the extracellular vesicles in the specific lesion tissues.

Provided are compositions and methods for treating Lewis Y antigen positive cancers in mammalian subjects by administering an effective amount of a radionuclide-labeled Lewis Y antigen targeting agent such as an antibody labeled with an alpha particle-emitting radionuclide such as 225Ac. The methods may further include administration of additional agents, such as radiosensitizing agents, immune checkpoint therapies, CD47 blockades, and / or DNA damage response inhibitors.

The present invention belongs to the field of animal vaccines, and specifically relates to a multi-epitope fusion protein of Gramseria parasuis antigens targeting multiple serotypes and its application. The applicant conducted proteomic analysis on four clinical isolates of Gramseria parasuis serotypes 4, 5, and 13 with high virulence and good immunogenicity, and screened out 8 antigenic proteins. The 8 screened antigenic proteins were further analyzed, and finally an immunogenic multi-epitope fusion protein of antigens that can recognize the three serotypes was obtained. As a vaccine, the fusion protein achieved a 100% protection rate against piglets infected with the clinically isolated serotype 4 strain HB04, the serotype 5 strain SJZ05, and the serotype 13 strain GD20.

The invention relates to the technical field of biological medicine, and discloses a lentiviral vector for specifically targeting a target cell and a construction method and application thereof, the lentiviral vector comprises: (1) an antigen targeting artificial protein receptor, the receptor comprising a target cell surface antigen binding domain and a transmembrane domain; (2) a mutated Moreton vesicular disease virus envelope protein; and (3) an expression cassette, wherein the expression cassette comprises a heterologous transgene. The novel lentiviral vector based on the mutated Moreton vesicular disease virus envelope, provided by the invention, can realize specific infection on target cells in vitro and in vivo, and compared with a vesicular stomatitis virus envelope VSV-G, the lentiviral vector constructed based on mutated Moreton vesicular disease virus envelope protein is better in stability in serum, and has a good application prospect. The efficiency of specifically infecting target cells is higher, and the drug effect in a mouse tumor model is more prominent.

The application provides a self-assembled ferritin nanovaccine targeting tuberculosis subunit antigens and a preparation method and application thereof, and belongs to the technical field of biological medicines. The application provides a subunit nanoparticle, selects ESAT-6 (E6), CFP-10 (C10) and ESAT-6-CFP-10 (EC) proteins as antigen target points, takes ferritin as a potential presentation carrier of TB epitope target points, fuses the E6, C10 and EC antigens into the ferritin, successfully self-assembles into a uniform epitope nanovaccine, has better immunogenicity, and can trigger a high-efficiency cellular immune response and immune memory. The application also uses an expression system method to complete expression and production of the subunit nanoparticle, and has economy and is suitable for large-scale production.

This invention relates to recombinant mammalian cells and their use in treating cancer. The present invention specifically relates to the co-expression of an adapter CAR and a conventional CAR in CAR T cells and the use of these cells in treating lymphoma. The invention also relates to pharmaceutical compositions comprising such recombinant mammalian cells, as well as their uses in cancer therapy.

Disclosed is a chemical synthesis method for Pseudomonas aeruginosa O5 serotype O-antigen oligosaccharide, which belongs to the field of chemical synthesis. In the disclosure, O-antigen trisaccharide is constructed with a D-glucuronic acid building block and a D-fucosamine building block, where the stereoselective synthesis of a 1,2-α-cis-glycosidic bond of D-fucosamine depends on remote acyl participation and reagent regulation, and synthesis of two types of 1,2-β-trans-glycosidic bonds of 2,3-diaminomannuronic acids is achieved via SN2 nucleophilic substitution of azido at position C2; and via selective assembly of protecting groups, orthogonal modification of modifying groups, and regulation of the reactivity of glycosyl donors and acceptors, multifunctional modified O-antigen target trisaccharide is successfully prepared. According to the method in the disclosure, the raw materials are cheap and easily available, and the preparation method is simple and easy to repeat. Therefore, the method has a very good application prospect in developing vaccines against P. aeruginosa.

The invention relates to the technical field of medicine, in particular to an identification method and an identification system of a tumor fusion gene neoantigen. According to the method, a standardized gene fusion new antigen clinical screening system is established by combining specific gene fusion in tumors on the basis of the advantages of nanopore sequencing gene fusion new antigens. In practical application, the system is researched and developed to enable a user to visually screen new antigens according to scores and rankings of the new antigens, compared with a traditional fusion gene new antigen screening method, more reliable new antigen targets with higher immunogenicity can be provided for patients, tumor immunotherapy schemes suitable for the patients can be screened out, and the purposes of optimizing treatment strategies and improving the tumor immunotherapy efficiency are achieved. Clinical diagnosis and treatment are enabled, and personalized treatment decision support is provided for patients.

The present disclosure relates to multispecific molecules comprising a peptide-MHC complex and an immune cell antigen targeting moiety. Particular embodiments relate to multimeric (e.g., dimeric) molecules comprising a peptide-MHC complex, an immune cell antigen targeting moiety, and a multimerization moiety. The present disclosure further provides pharmaceutical compositions comprising the multispecific molecules, and methods of using the multispecific molecules in antigen-specific T cell activation, in inducing antigen-specific immune responses, and in therapeutic applications, as well as nucleic acids encoding the multispecific molecules, recombinant cells expressing the multispecific molecules, and methods of producing the multispecific molecules.

The present invention provides protective monoclonal antibodies targeting Nipah virus (NiV) G protein and their uses, wherein the monoclonal antibodies can recognize Nipah virus G protein. The present invention uses NiV G protein as an antigen target, displays antigens on a ferritin nanoparticle platform to immunize mice, and screens out two monoclonal antibodies LN1F9 and LN1D11 that can specifically bind to NiV G protein. In vitro neutralization experiments have shown that these two antibodies have high neutralizing activity against both NiV-M and NiV-B strains, among which LN1F9 can also neutralize Hendra virus (HeV) of the same genus. The monoclonal antibodies LN1F9 and LN1D11 can effectively treat hamsters infected with NiV and prevent NiV infection in hamsters. They have extremely high application value in clinical treatment and prevention of NiV and HeV infection, and can be used to prepare detection products and preventive and therapeutic drugs for NiV and HeV.

The present invention relates to a dual antigen-targeting protein complex comprising an antibody or its antigen-binding fragment and an affibody. More specifically, the dual antigen-targeting protein complex comprises an EGFR (Epidermal Growth Factor Receptor) or PSMA (Prostate Specific Membrane Antigen) target site containing an antibody or its antigen-binding fragment, and a CD137 target site containing an affibody bound to the antibody or its antigen-binding fragment. When the dual antigen-targeting protein complex or a composition containing it is used, cancer can be effectively prevented or treated.

The present invention relates to a human papillomavirus antigen peptide and its application, belonging to the technical field of immunomedicine. The antigen peptide comprises the amino acid sequence shown in SEQ ID NO.1, or a small peptide having more than 90% similarity to the amino acid sequence shown in SEQ ID NO.1. The above-mentioned human papillomavirus antigen peptide is a new target located in the E7 gene of the HPV16 genome. This target is not expressed in normal human tissues during viral genome expression and can be used as an antigen target for applications in reagents, drugs, or vaccines for the diagnosis, treatment, and prognosis determination of clinical HPV16 / 18 infections or HPV16 / 18-positive tumors such as cervical cancer, esophageal cancer, head and neck cancer, oropharyngeal cancer, anogenital cancer, etc. For example, through adoptive T cell immunotherapy, it may bring new treatment possibilities to patients with advanced recurrent cervical cancer.

The present disclosure provides compositions and methods for targeting a Ras antigen to, for example, treat or prevent cancer. Disclosed embodiments include binding proteins, such as T cell receptors bind to a Ras antigen:HLA complex.Disclosed binding proteins are highly sensitive to antigen, capable of inducing activation of host T cells at low concentrations of peptide antigen. In certain embodiments, binding proteins of the present disclosure are non-alloreactive against, are substantially non-alloreactive against, and / or have a low risk of alloreactivity against (i) amino acid sequences from the human proteome and / or (ii) against human HLA alleles. Polynucleotides encoding such binding protein can introduced into a host cell, such as a T cell, and the cell can be used in immunotherapy for treating various cancers.

Anti-EphA2 antibody-drug conjugates that bind to human oncology targets are disclosed. The antibody-drug conjugates comprise a Bcl-xL inhibitor drug moiety and an anti-EphA2 antibody or antigen-binding fragment thereof that binds the antigen target, e.g., the antigen expressed on a tumor or other cancer cells. The disclosure further relates to methods and compositions for use in the treatment of cancers by administering the antibody-drug conjugates provided herein. Linker-drug conjugates comprising Bcl-xL inhibitor drug moiety and methods of making the same are also disclosed.

The invention belongs to the technical field of bioengineering, and particularly relates to a human helicobacter pylori UreB antigen as well as a preparation method and application thereof. The human helicobacter pylori UreB antigen has an amino acid sequence as shown in SEQ ID NO: 2; or an amino acid sequence which is formed by replacing, deleting or adding one or more amino acids to the amino acid sequence as shown in SEQ ID NO: 2 and has the same function as the amino acid sequence as shown in SEQ ID NO: 2. UreB glycoprotein of a main epidemic virus strain NCTC11637 of human helicobacter pylori is selected as antigen protein, through biological information analysis, amino acids of a full-length target sequence 1-572 of the UreB antigen are selected, the target sequence is synthesized into a target sequence, a GST tag is inserted, a recombinant plasmid expression vector is constructed, the recombinant plasmid expression vector is expressed and purified in an escherichia coli prokaryotic system and verified at the same time, and the UreB antigen is obtained. The obtained human helicobacter pylori UreB antigen has the characteristic of high expression, can be specifically combined with human helicobacter pylori, and has important clinical significance.

The invention relates to the technical field of biological medicine, and discloses a lentiviral vector and a construction method and application thereof, the lentiviral vector comprises: (1) an antigen-targeted artificial protein receptor, the receptor comprising a target cell surface antigen binding domain and a transmembrane domain; (2) a mutated Maraba virus envelope protein; and (3) an expression cassette, wherein the expression cassette comprises a heterologous transgene. The novel lentiviral vector based on the mutated Maraba virus envelope provided by the invention can realize specific infection on target cells in vitro and in vivo, and compared with a vesicular stomatitis virus envelope VSV-G, the lentiviral vector constructed on the basis of the mutated Maraba virus envelope protein has better stability in serum, and can be used for preparing a novel lentiviral vector of the mutated Maraba virus envelope. The efficiency of specifically infecting target cells is higher, and the drug effect in a mouse tumor model is more prominent.

The present disclosure provides linker-payload conjugates including a bioorthogonal group and a hydrophilic moiety. The improved linker-payloads for antibody conjugation and improved antibody drug conjugates (ADCs) exhibit greater stability in blood circulation and enhanced drug delivery and drug release efficiencies in target cells. The present disclosure also relates to antibodies and antigen-binding fragments thereof for several antigen targets (e.g. TROP2, HER2, Nectin-4, etc.), as well as pharmaceutical compositions including ADCs. Also described herein are methods of using ADCs for treatment of subjects associated with pathological conditions.

This invention discloses an environmental detection method for underwater multi-autonomous robotic fish. First, an interconnected, coupled, immune-cooperative detection model of underwater multi-autonomous robotic fish is constructed and its parameters are initialized. The robotic fish acquires environmental information about surrounding obstacles and the detected area, and identifies the original antigens of the obstacles. E o and the original antigens in the detected areas E d The invention identifies the decomposition antigens targeting obstacles and detected areas, thereby determining the antibody concentrations of the robotic fish and selecting antibodies based on these concentrations. Based on the behavior of the selected antibodies, the robotic fish completes the next step of detection until the entire detection process is finished. This invention uses the robotic fish's environment as an antigen, the robotic fish as a B cell, and its behavior as antibodies. It constructs an interconnected and coupled immune collaborative detection network targeting obstacles and detected areas, achieving a balance in the robotic fish's processing of two types of environmental information. This improves the coverage of environmental detection, reduces detection duplication, and enables the robotic fish to move rapidly and effectively in unknown and complex environments, thus improving detection efficiency.

The present disclosure provides linker-payload conjugates including a cysteine-reactive group and a hydrophilic moiety. The improved linker-payloads for biomolecules conjugation and improved drug conjugates exhibit greater stability in blood circulation and enhanced drug delivery and drug release efficiencies in target cells. The present disclosure also relates to antibodies and antigen-binding fragments thereof for several antigen targets (e.g. cMET, HER3, EGFR, TROP2, HER2, Nectin-4, etc.), as well as pharmaceutical compositions including ADCs. Also described herein are methods of using ADCs for treatment of subjects associated with pathological conditions.

There remains a need for more effective methods and dosing regimens for treating subjects with FRA-expressing cancers with anti-FRA ADCs, such as MORAb-202, e.g., that reduce the side effects of treatment. [Solution] Linker toxins and antibody-drug conjugates are disclosed that bind to human oncology antigen targets, such as folate receptor alpha, and / or provide anti-tubulin drug activity. The linker toxins and antibody-drug conjugates contain an eribulin drug moiety and can be internalized into target antigen-expressing cells. The disclosure further relates to methods and compositions for use in treating cancer by administering the antibody-drug conjugates provided herein.